1988年6月～1992年1月经导管肝动脉灌注化疗及栓塞术治疗不能切除的原发性肝癌70例,男64例,女6例.年龄23岁～66岁,中位年龄47.6岁.Ⅱ期57例,Ⅲ期13例.采用Seldinger氏插管法.治疗方式分3种:TAI、LP—TAE及LP+GS-TAE.经治疗80％病人临床症状改善,疼痛减轻或消失,肿瘤缩小.67.6％病人AFP降低或转阴.生存期延长,半年、1年、2年及3年总生存率分别为62.1％(41/66)、42％(21/50)、34.6％(9/26)及31.6％(6/19).研究表明LP十GS-TAE对不能手术切除的肝癌患者应作为首选疗法. From June 1988 to January 1992, transcatheter arterial infusion chemotherapy and embolization were used to treat 70 cases of unresectable primary liver cancer. There were 64 males and 6 females. The age ranged from 23 to 66 years and the median age was 47.6 years. II There were 57 patients in Phase III and 13 in Phase III. Seldinger’s intubation was used. The treatment was divided into 3 types: TAI, LP-TAE, and LP+GS-TAE. After treatment, 80% of patients had clinical symptoms improved, pain reduced or disappeared, and tumors were reduced. In the 67.6% of patients, the AFP decreased or turned negative. The survival time was prolonged. The six months, one year, two years, and three years overall survival rates were 62.1% (41/66), 42% (21/50), and 34.6% (9/ 26) and 31.6% (6/19). Studies have shown that LP ten GS-TAE should be the first choice for patients with unresectable liver cancer.